Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection

Autor:	Danny Cheng, Daniel Dexter, Saket Badle, Prabal Mittal, Alasdair Bamford, Phil Ancliff, David O'Connor, Srdan Rogosic, Joe Brierley, Katharine Orf, Pascale du Pré, Sujith Samarasinghe, Garth Dixon, Jack Bartram, Sara Ghorashian, Vesna Pavasovic, Louis Grandjean, Caroline Dalton, Ajay Vora, Anupama Rao
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Induction chemotherapy Immunosuppression Newly diagnosed Hematology 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Concomitant hemic and lymphatic diseases Pandemic medicine Lymphoblastic leukaemia Letters business 030215 immunology
Zdroj:	British Journal of Haematology
ISSN:	1365-2141 0007-1048
Popis:	The COVID‐19 pandemic potentially makes treatment of acute leukaemia more difficult. Most induction chemotherapy regimens for acute leukaemia lead to extended periods of cytopaenia and immunosuppression rendering patients vulnerable to opportunistic infections. As with many aspects of SARS‐CoV‐2, there is no universally accepted way of treating patients who present with acute leukaemia and associated infection.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::280a1175f07786bbd4e81d85918ed928 http://europepmc.org/articles/PMC7404383 Zobrazit plný text záznamu Plný text